Skip to content
Screener

Kailera Therapeutics KLRA Other Income (Expense)

Other Income (Expense) at other companies

Veradermics logo
VeradermicsMANE
$2.63M+411%
GPA
General Purpose Acquisition Corp.GPAC
-$1.25M-164%
Dycom Industries logo
Dycom IndustriesDY
-$1.51M-121%
Target logo
TargetTGT
$15M-42.3%
Edison International logo
Edison InternationalEIX
$121M+13.1%
Analog Devices logo
Analog DevicesADI
-$54.85M-5.5%

Other financials

Income statement

See full
Operating income-$84.7M-314%
Net income-$78.9M-339%
EPS (diluted)-$3,650.00+79.7%

Balance sheet

See full
Cash & equivalents$111.8M+9.9%
Total debt$10.5M—
Total equity-$432.1M-83.7%
Total assets$624.8M—

Cash flow

See full
Operating cash flow-$68.3M-275%

Valuation

See full
Market cap$2.44B-15.8%
Enterprise value$2.34B—

Returns & leverage

See full
Debt / equity-0×—
Current ratio9.7×—

Where this comes from

Reported directly by Kailera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026.

Filed
May 26, 2026, 4:29 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-239417
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Other income
Interest income5,7161,675
Other income, net79800
Total other income5,7952,475
Net loss$(78,865)$(17,983)
Other comprehensive loss
Unrealized loss(761)(6)
Comprehensive loss(79,626)(17,989)

Item 1. Financial Statements.

FAQ

What is Kailera Therapeutics's other income (expense)?
Kailera Therapeutics (KLRA) reported other income (expense) of $5.8M in Q1 2026.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Kailera Therapeutics's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude